Serum-based ALYGNSA immunoassay for the prostate cancer biomarker, total prostate-specific antigen (tPSA).
Prostate-specific antigen (PSA) is a serum glycoprotein overproduced by the prostate in prostate cancer (> or = 4 ng/mL in the bloodstream). An immunoassay for total PSA (tPSA) was developed using the ALYGNSA method to enhance capture antibody orientation and a limit of detection of 0.63 ng/mL was reported, a limit 15-fold lower than a commercial tPSA ELISA assay. This ALYGNSA assay, however, was performed using only buffer-based proteins and blocking agents (Mackness et al., Anal Bioanal Chem 396:681-686, 2010). To improve the clinical application of this system, a serum-based tPSA ALYGNSA was developed employing human serum. This assay also resulted in a limit of detection of 0.63 ng/mL of tPSA protein. The findings reported here provide support for the clinical application of this assay for diagnosis, progression, treatment, and possible recurrence of prostate cancer.
Mackness
Brian C
BC
Biochemistry Program, Department of Chemistry, College of Arts and Sciences, University of Massachusetts Lowell, Lowell, MA 01854, USA.
McDonald
Melisenda J
MJ
D015415:Biomarkers / Q000097:blood; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D057230:Limit of Detection; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood*
D015415:Biomarkers; D017430:Prostate-Specific Antigen